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A hallmark of prostate cancer progression is dysregulation of lipid
metabolism via overexpression of fatty acid synthase (FASN), a
key enzyme in de novo fatty acid synthesis. Metastatic castration-
resistant prostate cancer (mCRPC) develops resistance to inhibitors
of androgen receptor (AR) signaling through a variety of mecha-
nisms, including the emergence of the constitutively active AR
variant V7 (AR-V7). Here, we developed an FASN inhibitor (IPI-
9119) and demonstrated that selective FASN inhibition antago-
nizes CRPC growth through metabolic reprogramming and results
in reduced protein expression and transcriptional activity of both
full-length AR (AR-FL) and AR-V7. Activation of the reticulum en-
doplasmic stress response resulting in reduced protein synthesis
was involved in IPI-9119–mediated inhibition of the AR pathway.
In vivo, IPI-9119 reduced growth of AR-V7–driven CRPC xenografts
and human mCRPC-derived organoids and enhanced the efficacy
of enzalutamide in CRPC cells. In human mCRPC, both FASN and
AR-FL were detected in 87% of metastases. AR-V7 was found in
39% of bone metastases and consistently coexpressed with FASN.
In patients treated with enzalutamide and/or abiraterone FASN/
AR-V7 double-positive metastases were found in 77% of cases.
These findings provide a compelling rationale for the use of FASN
inhibitors in mCRPCs, including those overexpressing AR-V7.
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The current use of second-generation antiandrogens such asenzalutamide (Enza) or androgen synthesis inhibitors such as
abiraterone (Abi) has improved quality of life and survival of
patients with metastatic castration-resistant prostate cancer
(mCRPC) (1–3). However, most patients eventually progress to
develop treatment-refractory metastatic disease (4). Despite
castrate levels of circulating androgens in patients on androgen
deprivation therapy, persistent activation of the androgen receptor
(AR) axis still drives mCRPC (5). Different mechanisms of resistance
to AR-directed therapies have been described, including the emer-
gence of AR splice variants (AR-Vs), such as AR-V7 (6–8). AR-
V7 lacks the C-terminal ligand-binding domain of full-length AR
(AR-FL) and functions as a constitutively active, ligand-independent
transcription factor that drives growth of mCRPC cells in vitro and in
vivo (9). AR-V7 mRNA and protein are up-regulated in mCRPC
bone metastases (10) and associated with a decrease in overall sur-
vival (11) and resistance to Enza and/or Abi treatment (12).
In contrast to normal prostatic cells that rely mostly on diet-
derived lipids for fatty acids (FAs), prostate cancer (PCa) pro-
gression is marked by increasing rates of de novo FA synthesis,
independent of circulating lipid levels (13). The key enzyme, FA
synthase (FASN), catalyzes the synthesis of palmitate from
malonyl-CoA and acetyl-CoA using NADPH as the reducing
agent. The expression of enzymes in the lipogenic pathway,
including FASN, and transcriptional regulators such as the sterol
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regulatory element-binding proteins (SREBPs) is significantly
increased in PCa, especially in the mCRPC setting (14–16).
Besides providing structural lipids and bioenergetics to sustain
cancer cell growth, enhanced FASN activity is also associated
with several oncogenic mechanisms, including the activation of
the PI3K/Akt/mTORC1 pathway, palmitoylation of known on-
cogenes including k-RAS and WNT-1, regulation of endoplasmic
reticulum (ER) function to sustain membrane biogenesis (13,
17), and resistance to genotoxic insults (18). Inhibition of FASN
activity through genetic and pharmacological means suppresses
PCa cell growth by cell cycle arrest and/or apoptosis (13), while
FASN overexpression is linked to resistance to chemotherapy
(18). FASN expression is transcriptionally induced by AR
through the activation of SREBP1 (19) or by a direct binding to
FASN promoter regions (20). However, the evidence that
SREBP1 inhibition can down-regulate AR-FL levels (21) sug-
gests a mutual regulation between AR signaling and FA me-
tabolism. To test this, we developed a selective and potent FASN
inhibitor (IPI-9119). We used IPI-9119 to assess the metabolic
and biological effects of FASN activity suppression in CRPC,
including characterization of suppressive effects on AR-FL and
AR-V7. Collectively, these results provide strong rationale for
the design of future clinical trials with IPI-9119 in mCRPC.
Results
IPI-9119 Is a Potent, Selective, and Irreversible Inhibitor of FASN. We
developed an irreversible FASN inhibitor (IPI-9119) (Fig. 1A).
IPI-9119 inhibits the FASN thioesterase domain by promoting
acylation of the catalytic serine (SI Appendix, Fig. S1A). IPI-
9119 showed high potency against human purified FASN in an
in vitro biochemical assay (IC50 = 0.3 nM), with high selectivity
and negligible off-target activity (SI Appendix, Fig. S1B).
We tested FASN activity in androgen-dependent (AD) (LNCaP)
and -independent (AI) (22Rv1, LNCaP-95) PCa cell lines at 3 or
6 d of incubation with IPI-9119. After 3 d of treatment, 0.05 μM
IPI-9119 induced complete blockade of FASN activity. In contrast,
it appeared that 0.1 μM IPI-9119 was required to sustain FASN
inhibition for 6 d since FASN activity in PCa cells treated with
0.05 μM IPI-9119 was highly variable (Fig. 1B and SI Appendix, Fig.
S1C). We noted increased FASN protein and mRNA expression in
cells following 6 d of treatment (Fig. 1 C–E), suggesting a com-
pensatory mechanism that required drug concentrations higher than
0.05 μM to overcome. This was also evident from RNA sequencing
(RNA-seq) data of IPI-9119-treated PCa cells, which revealed
broad up-regulation of lipogenic genes, as previously demonstrated
with other FASN inhibitors (22, 23) (SI Appendix, Fig. S2 and
Dataset S1A). Concentrations of IPI-9119 between 0.1 and 0.5 μM
were selected for further investigation.
FASN Inhibition Blocks Cell Growth and Induces Apoptosis. We an-
alyzed cell growth, cell cycle kinetics, and apoptosis across a
panel of AR-positive, AD (LNCaP), AI (C4-2, C4-2B, LNCaP-
Abl), and Enza/Abi-resistant AI cell lines harboring the AR-
V7 splice variant (22Rv1, LNCaP-95). IPI-9119 inhibited cell
growth (Fig. 2A and SI Appendix, Fig. S3A) and clonogenic
survival (Fig. 2B) in PCa cell lines to a much greater extent than
in the immortalized, nontransformed RWPE-1 cell line (SI Ap-
pendix, Fig. S3B). No growth inhibition by IPI-9119 was observed
in FASN KO PCa cells (SI Appendix, Fig. S3 C and D), con-
firming the specificity of IPI-9119 for FASN. Moreover, the
antitumor effect of IPI-9119 was preserved in culture medium
with whole serum compared with lipid-reduced serum (SI Ap-
pendix, Fig. S3E). Cell growth inhibition by IPI-9119 was rescued
by the addition of exogenous palmitate, confirming that the ef-
fects on cell growth and survival were due to on-target activity
and that palmitate rather than the toxic accumulation of
malonyl-CoA accounts for the IPI-9119–mediated anticancer
effect (Fig. 2C). IPI-9119 reduced the proportion of S-phase cells
and increased that of G0/G1- and sub-G1–phase cells (Fig. 2D
and SI Appendix, Fig. S4A) and decreased expression of cyclin
A2 (Fig. 2E). Analysis of Parp cleavage, Annexin V, and propi-
dium iodide staining showed induction of apoptosis by IPI-9119
(Fig. 2E and SI Appendix, Fig. S4 B and C).
FASN Inhibition Alters the PCa Metabolome. The metabolic conse-
quences of FASN activity suppression were investigated by an
unbiased, global approach using untargeted MS-based metab-
olomics as well as biochemical assays and lipid staining. The




Fig. 1. IPI-9119 is a potent and selective FASN inhibitor. (A) Chemical structure of
IPI-9119 (IPI). (B) FASN activity in AD (LNCaP) and AI (22Rv1, LNCaP-95) cells, fol-
lowing 6-d (6d) treatment with IPI at the indicated concentrations. Data are
expressed as the mean activity ± SD (n = 3) and plotted as percent DMSO. ****P <
0.0001, ***P < 0.001, one-way ANOVA followed by Tukey’s post hoc test. (C)
Representative immunoblotting of FASN expression under IPI treatment. (D)
Densitometric analysis. Data are expressed as normalized (FASN/β-actin) arbitrary
units (AU) ± SD (n = 3) and plotted as percent DMSO. ***P < 0.001, **P < 0.01,
*P < 0.05, one-way ANOVA, followed by Tukey’s post hoc test. (E) FASN mRNA
levels measured by real-time qPCR. Data were normalized using β-actin as house-
keeping and expressed as n-fold DMSO ± SD (n = 3 per concentration). *P < 0.05,
***P < 0.001, ****P < 0.0001, one-way ANOVA followed by Tukey’s post hoc test.
Significance
Standard of care for metastatic castration-resistant prostate
cancer (mCRPC) mainly relies on suppression of androgen re-
ceptor (AR) signaling. This approach has no lasting benefit due
to the emergence of resistance mechanisms, such as ligand-
independent splicing variant AR-V7. A metabolic feature of
mCRPC is the upregulation of de novo lipogenesis to provide
substrates and fuel for metastatic spread. Whether increased
levels of fats affect AR signaling to promote an aggressive
disease remains to be determined. Using a selective and potent
inhibitor of fatty acid synthase we demonstrate that suppres-
sion of this key enzyme inhibits AR, most importantly AR-V7,
and reduces mCRPC growth. Our findings offer a therapeutic
opportunity for mCRPC and a potential mechanism to over-
come resistance to AR inhibitors.
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IPI-9119 suppressed de novo FA synthesis and neutral lipid ac-
cumulation. We also found that IPI-9119 inhibited FA oxidation
(FAO) due to malonyl-CoA accumulation (measured as malonyl-
CoA carnitine, discussed below), resulting in the inhibition of the
carnitine palmitoyltransferase 1 enzyme and FAO suppression
(Fig. 3 A–C), as previously described (24). Metabolic profiling
was performed in cell lysates of LNCaP, 22Rv1, and LNCaP-
95 cells exposed to IPI-9119 or DMSO for 6 d. A marked sep-
aration of samples treated with IPI-9119 from control groups
(independent of the drug concentration) was observed based on
the entire metabolic profile (Fig. 3D). Ninety-one of 418 me-
tabolites were significantly modulated by IPI-9119 treatment
(both 0.1 and 0.5 μM) in all of the cell lines analyzed [P <
0.05; false discovery rate (FDR) < 0.05] (SI Appendix, Fig. S5
and Dataset S1B). These included metabolites involved in lipid
metabolism as well as amino acid, TCA cycle, carbohydrate, and
nucleotide metabolism. Gene set enrichment analysis (GSEA)
using RNA-seq data confirmed down-regulation of pathways
associated with amino acid and protein translation (i.e., LNCaP
cells), as well as purine and pyrimidine synthesis (i.e., 22Rv1 and
LNCaP-95 cells) (Dataset S1C). As expected from the suppres-
sion of de novo lipogenesis, significant reduction of the two most
common FAs derived from palmitate, namely oleic and palmi-
toleic acids, and accumulation of polyunsaturated FAs (doco-
sapentaenoic acid, docosahexaenoic acid, eicosapentaenoic acid,
and arachidonate) (Fig. 3E, SI Appendix, Fig. S6, and Dataset
S1B) were observed. Moreover, enhanced phospholipid remod-
eling (e.g., decrease in phosphoethanolamine species in favor to
phosphatidylcholine) was induced in LNCaP and LNCaP-95 cells
(Dataset S1B). Thus, while RNA-seq data highlighted compen-
satory transcriptional up-regulation of FA synthesis genes/regu-
lators by IPI-9119, the intracellular metabolic changes confirmed
the suppression of FASN activity.
Following blockade of FA synthesis, unused acetyl-CoA can
be redirected toward the cholesterol pathway. Increased in-
tracellular cholesterol levels were detected in all cell lines (SI
Appendix, Fig. S7A). Accordingly, GSEA highlighted the up-
regulation of cholesterol synthesis and steroidogenesis path-
ways (SI Appendix, Fig. S7B). MS-based analyses, however, did
not reveal any significant increase in testosterone or dihy-
drotestosterone levels (Dataset S1D). Alterations in metabolic
pathways other than FA synthesis (e.g., glutamine/glutamate,
branched-chain amino acids, and glycogen metabolism) were
observed in a cell-type-specific manner (SI Appendix, Fig. S6).
Taken together, our data suggest that IPI-9119 profoundly alters
FA metabolism, affecting both synthetic and catabolic reactions,
and also impacts several related metabolic pathways.
Suppression of FA Synthesis Inhibits AR-FL and AR-V7 Expression.
Since AR signaling and lipid metabolism are tightly linked, we
tested the effect of the inhibition of de novo lipogenesis on AR
signaling by analyzing AR expression in both AD and AI cell
lines that display various patterns of AR-FL and AR-V7 expression.
IPI-9119 significantly decreased AR-FL protein levels in AD
LNCaP and AI C4-2 cells (expressing only AR-FL) and reduced
the expression of AR-V7 in LNCaP-95 and 22Rv1 AI cells driven
by this variant. Prostate-specific antigen (PSA) protein was also
significantly down-regulated in AD LNCaP but not in AI cells
(Fig. 4A and SI Appendix, Fig. S8A). Addition of exogenous
palmitate reversed these effects, confirming that blockade of
FASN activity impacts the AR/AR-V7 pathway (Fig. 4B). To
rule out that AR/AR-V7 reduction was simply due to IPI-9119–
mediated cell cycle arrest, treatment with the DNA replication
inhibitor aphidicolin was used to mimic S phase inhibition. De-
spite aphidicolin-mediated complete suppression of S phase




Fig. 2. IPI-9119 inhibits PCa cell growth and induces
cell cycle arrest and apoptosis. (A) Measurement of
cell growth after 6-d treatment with IPI-9119 (IPI).
Data are expressed as the mean number of viable
cells ± SD (n per concentration = 24 for LNCaP; 15 for
22Rv1; 12 for LNCaP-95) and plotted as percent DMSO.
****P < 0.0001, one-way ANOVA followed by Tukey’s
post hoc test. (B) Clonogenic assay, following 3-wk
treatment with IPI or DMSO. Representative images of
colony formation (Left) and quantification (Right). Data
are expressed as the mean OD ± SD (n = 3). **P < 0.01,
***P < 0.001, ****P < 0.0001, one-way ANOVA fol-
lowed by Tukey’s post hoc test. (C) Cell growth rescue
by exogenous palmitate. Data are expressed as the
mean growth ± SD (n per concentration = 9) and
plotted as percent DMSO. ****P < 0.0001 IPI vs. DMSO,
####P < 0.0001 IPI + palmitate vs. IPI, two-way ANOVA
followed by Sidak’s post hoc test. (D) Flow cytometry
using propidium iodide (PI) and bromodeoxyuridine
(BrDU), following IPI treatment (6 d). Data are expressed
as the mean percent ± SD (n = 6). **P < 0.01, ***P <
0.001, ****P < 0.0001, two-way ANOVA followed by
Sidak’s post hoc test. (E) Representative immunoblot-
ting of cell cycle and apoptosis markers. Experiment was
repeated twice. The S-phase inhibitor aphidicolin (Aphi,
0.3 μg/mL, 3 h) and the apoptosis inducer staurosporine
(Stauro, 1 μM for 24 h) were used as positive controls.
n = number of independent samples.











observed (SI Appendix, Fig. S8B). These results suggest that the
inhibition of AR-FL/AR-V7 protein levels is not simple reflec-
tion of IPI-9119–mediated cell cycle arrest.
To further clarify how IPI-9119 reduces AR and AR-V7 levels,
we first determined the effects of IPI-9119 on AR-FL and AR-
V7 expression at the transcriptional level by real-time qPCR.
While AR-FL mRNA was significantly reduced in IPI-9119-
treated LNCaP, no significant effect on AR transcripts other
than mild down-regulation of AR-V7 in 22Rv1 was observed in
AI lines (Fig. 4C). Confirmation that AR-V7 was mainly regu-
lated at the protein level came after administering IPI-9119 to
LNCaP cells stably overexpressing AR-V7 under the inducible
TRE3G promoter. Ectopic AR-V7 protein expression was sig-
nificantly reduced by IPI-9119 treatment (Fig. 4D). The use of a
second FASN inhibitor (TVB-3166) (SI Appendix, Fig. S8C) and
FASN knockdown (KD) (SI Appendix, Fig. S8 D and E) or KO
(SI Appendix, Fig. S3D) recapitulated the effect of IPI-9119 on
AR-FL and AR-V7 proteins. Furthermore, the expression of
nuclear AR-FL and AR-V7 was dramatically diminished by IPI-
9119 in all of the PCa cell lines analyzed (SI Appendix, Fig. S9 A
and B). Finally, the expression of key proteins of pathways as-
sociated with cell survival, proliferation, and energy stress (i.e.,
Akt/S6RP/4E-BP1, MAPK, beta-catenin, STAT3, AMPK) was
analyzed to exclude that AR/AR-V7 reduction is a mere result of
global cell stress response. Neither significant inactivation of
these pathways nor activation of the energy sensor AMPK was
observed (SI Appendix, Fig. S10). Rather, increased phosphory-
lation of Akt was observed in both LNCaP and LNCaP-95 cells
concomitant to IPI-9119–mediated AR/AR-V7 reduction, sug-
gesting a compensatory reciprocal feedback, as previously described
(25). Only c-MYC and AR/AR-V7 proteins were consistently
reduced in all of the models analyzed (Fig. 4 and SI Appendix,
Fig. S10).
IPI-9119 Induces ER Stress and AR/AR-V7 Protein Translation
Inhibition. Changes in membrane lipid composition, including
increased phosphatidylcholine/phosphatidylethanolamine ratio
and increased free cholesterol levels induce ER stress (26–28).
Our metabolomics as well as metabolite set enrichment analyses
(MSEA) using lipidomics data confirmed these alterations fol-
lowing IPI-9119 treatment (Dataset S1 B and E–I). FASN
inhibition-induced ER stress was previously associated with in-
creased phosphorylation of the translation initiation factor
eiF2α, reduction in cellular protein synthesis, and induction of
apoptosis (17). Moreover, alteration of calcium (Ca2+) homeo-
stasis induced by the ER stress inducer thapsigargin (Tg) or Ca2+
ionophore was reported to inhibit Cap-dependent AR protein
synthesis and to induce AR degradation, respectively (29, 30).
Therefore, we assessed whether induction of ER stress was as-
sociated with IPI-9119–mediated reduction in AR-FL/AR-
V7 protein synthesis and antiproliferative effects. We confirmed
increased phosphorylation of eiF2α starting at 3 d of treatment
with IPI-9119 and global protein synthesis reduction (Fig. 5 A
and B). Accordingly, we observed IPI-9119–mediated reduction
of protein translation cofactor eiF4B, recently involved in FASN-
mediated oncogenic translation (31) (Fig. 5C). To corroborate
the link between induction of ER stress and reduction of AR axis,
we used the ER stressor Tg at early time points (12 h) where cell
growth inhibition was not evident yet (SI Appendix, Fig. S11A).




Fig. 3. IPI-9119 induces a profound metabolic reprog-
ramming in PCa cells. (A) Incorporation of [14C]glucose
into lipids, following treatment with IPI-9119 (IPI).
Results are expressed as counts per minute (cpm),
normalized to protein content. Mean values ± SD are
shown (n = 6); ****P < 0.0001, Student t test. (B) Fatty
acid oxidation measured by 14C-CO2 release. Results
are expressed as cpm normalized to protein content.
Data are expressed as the mean ± SD (n = 4), nor-
malized to protein content; ***P < 0.001, Student
t test. (C) Neutral lipids accumulation in lipid droplets.
Representative images (magnification: 100×) of Oil
Red O staining. Quantification of neutral lipids accu-
mulation is shown next to the images. Data are
expressed as the mean absorbance ± SD (n = 3);
****P < 0.0001, Student t test. (D) Principal compo-
nent analysis of the PCa cell lines analyzed (n = 6 per
condition). (E) Box plots showing the levels of key
metabolites involved in lipid metabolism from metab-
olomics data, (n = 6 per condition). ***q < 0.001, **q <
0.01, *q < 0.05, Student t test. n = number of inde-
pendent samples.
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a 1-h pretreatment with an ER stress inhibitor, the Ca2+ chelant
bapta (20 μM), partially restored its expression. Similar results were
obtained when ER stress was inhibited using the PERK inhibitor
GSK 2606414 (100 nM, 24 h) (Fig. 5 D and E). Accordingly, treat-
ment with the specific inhibitor of the eiF2α phosphatase, salubrinal,
induced AR/AR-V7 reduction (SI Appendix, Fig. S11B). These re-
sults suggest that ER stress is involved in inducing AR pathway down-
regulation. Finally, addition of exogenous palmitate ameliorates ER
stress markers while rescuing both AR/AR-V7 expression (Fig. 5F)
and IPI-9119–induced cell growth inhibition (Fig. 2C). We confirmed
these findings using FASN KO models (SI Appendix, Fig. S11C).
Altogether, these data suggest the participation of ER stress in me-
diating the anticancer effect of FASN inhibition (Fig. 5G) in concert
with other mechanisms, first and foremost the reduction of lipid
membrane synthesis. No evident induction of autophagy was ob-
served in association with ER stress (SI Appendix, Fig. S11D).
Suppression of FA Synthesis Inhibits AR-FL and AR-V7 Transcriptional
Activity. Analysis of both RNA-seq and real-time qPCR data
from LNCaP cells treated with IPI-9119 revealed reduced ex-
pression of canonical AR-FL target genes (e.g., KLK3, TMRSS2,
and NKX3.1) (Figs. 4C and 6A). Accordingly, activity of an AR-
responsive luciferase reporter was inhibited by IPI-9119 in
LNCaP cells (Fig. 6B). Conversely, in LNCaP-95 cells, where
IPI-9119 primarily inhibits AR-V7, the expression of FKBP5 but
not KLK3 (PSA) was inhibited by IPI-9119 (Fig. 4C). We ob-
served suppression of an M-phase cell cycle gene signature
previously found to be associated with AR-V7 transcriptional
activity (32), also representing biphasic AR-FL targets (Fig.
6C) (7). Strikingly, this signature was completely restored by the
addition of exogenous palmitate (Fig. 6D and Dataset S1L).
More importantly, IPI-9119 inhibited a gene signature found in
CRPC bone metastases, which express high mRNA levels of AR-
V7 (33) (Fig. 6E). Similar results were obtained in 22Rv1 cells
(SI Appendix, Fig. S12 A and B). Moreover, we observed trending
down-regulation of a recently published AR-V7-modulated gene
set (33 up-regulated genes in common between LNCaP-95 and
22Rv1 cells) identified during analyses of AR-V7–regulated tran-
scriptome and cistrome (34) (SI Appendix, Fig. S12C). c-MYC, an
oncogene commonly amplified in CRPC, had been previously
described as an androgen-independent, AR-dependent target
gene, which we confirmed in this study (SI Appendix, Fig. S12D).
c-MYC protein was significantly reduced in IPI-9119–treated AD
and AI cells and rescued by exogenous palmitate (Fig. 6F). Preranked
GSEA also confirmed the down-regulation of a c-MYC transcrip-
tional signature (V1) (Fig. 6G). Thereafter, we investigated the role
of c-MYC in the response to IPI-9119 treatment. Thus, we treated
c-MYC–overexpressing PCa cells derived from Hi-MYC mice (35)
with IPI-9119 for 6 d. MYC-CaP cells showed significant cell growth
inhibition following IPI-9119 treatment (around 40% and 70% at
0.1 and 0.5 μM, respectively). These data suggest a mutual regulation
between FASN and c-MYC whereby c-MYC determines a de-
pendency on de novo FA synthesis and FASN inhibitors shut off this
key metabolic and oncogenic driver (SI Appendix, Fig. S12 E and F).
Finally, we went back to our findings of IPI-9119–mediated
reduction of AR-V7 protein to test the combination of IPI-
9119 and Enza in 22Rv1, a cell line resistant to Enza and
driven by AR-V7. Our data show that the combination of IPI-
9119 and Enza was more effective in reducing 22Rv1 cell growth
than either of the single agents (Fig. 6H).
FASN Inhibition Reduces Tumor Growth in CRPC Preclinical Models
and Human Organoids. To translate our in vitro findings into the
preclinical setting, we investigated the effect of IPI-9119 in
mouse models of CRPC resistant to Enza and/or Abi; 22Rv1 and
LNCaP-95–bearing xenografts were exposed to IPI-9119 with a
constant infusion (0.5 μL/h; 100 mg/mL) for 4 wk, using an s.c.
osmotic ALZET pump. Mice did not show any signs of toxicity,
stress, weight loss (SI Appendix, Fig. S13A), or changes in feeding
behavior. We observed significant inhibition of 22Rv1 xenograft
tumor growth at the end of the treatment (35% inhibition at end




Fig. 4. IPI-9119 inhibits AR-FL and AR-V7 protein ex-
pression. (A) Representative immunoblotting showing
the reduction of AR-FL and AR-V7 in AD and AI cells.
Experiment was repeated three times. (B) Representa-
tive immunoblotting showing palmitate-mediated res-
cue of AR-FL and AR-V7 inhibition. Palmitate (50 μM)
was complexed with BSA (molar ratio 6:1), while control
cells were treated with BSA only. Experiment was re-
peated three times. (C) Real-time qPCR of AR-FL/AR-
V7 and AR-target genes. Data are plotted as the mean
of three independent samples per condition and
expressed as fold of DMSO (set as 1) ± SD. (D) Repre-
sentative immunoblotting showing IPI-mediated ectopic
inhibition of AR-V7 in negative LNCaP cells using a
doxycycline-inducible AR-V7 construct. Experiment was
repeated three times, using independent infections.











reduced AR-V7 levels following 2 wk of treatment (Fig. 7B). Similar
results were obtained in mice bearing LNCaP-95 xenografts (33%
inhibition at end of treatment; P < 0.0016, Mann–Whitney U test)
(Fig. 7C), with concomitant intratumoral inhibition of FASN ac-
tivity (Fig. 7D). In line with the cell line data, cholesterol levels
and the expression of the key enzyme in cholesterol synthesis, 3-
hydroxy-3-methylglutaryl-CoA reductase were increased also in
vivo (SI Appendix, Fig. S13 B and C). Finally, we tested the effi-
cacy of IPI-9119 in MSK-PCa 3, which is a FASN- and AR-FL–
positive human mCRPC organoid line (36). An equal number
of cells were plated and organoids were grown for 25 d. We ob-
served significant reduction in organoid growth under treatment
with IPI-9119 (Fig. 7E), confirming the antitumorigenic effect of
FASN inhibition in human mCRPC.
FASN Protein Is Coexpressed with AR-FL and AR-V7 in Human mCRPC.
To explore opportunities for therapy with IPI-9119 in the clinical
mCRPC setting, we analyzed the expression of FASN, AR-FL,
and AR-V7 proteins in tissue microarrays from 61 mCRPC pa-
tients. Six neuroendocrine cases were excluded from the analysis.
Twenty-two of the remaining 55 cases were resistant to Enza and/
or Abi. FASN was detected in 91% of metastatic sites, in signifi-
cant association with AR-FL expression (87% of all metastases, P <
0.0001, Fisher’s exact test). AR-V7 positivity was observed in 39%
of bone metastases, and 12% of visceral sites, and consistently
coexpressed with FASN (Fig. 8 A and B and SI Appendix, Fig. S14).
All but one patient had at least one metastatic site coexpressing
FASN and AR-FL. In the Enza- and/or Abi-treated subset, FASN/
AR-V7 double-positive metastases were found in 77% of cases. In
addition, AR-V7 was detected in up to 25% of Enza/Abi treatment-
naïve cases, always coexpressed with FASN (Fig. 8C). Individual
FASN, AR-FL, and AR-V7 positivity and intensity for each case
and metastatic site are described in detail in Dataset S1M.
Taken together, these data provide the rationale for the use of
FASN inhibitors in mCRPC overexpressing AR-V7, in both
Enza- and/or Abi-resistant and -naïve patients.
Discussion
Metabolic reprogramming contributes to treatment resistance.







Fig. 5. IPI-9119 induces ER stress response and pro-
tein translation inhibition. (A) Immunoblotting show-
ing the induction of the ER stress marker p-eiF2α in
LNCaP and LNCaP-95 cells treated with IPI-9119 (IPI)
for 3 and 6 d. (B) SUnSET assay using lysates from
LNCaP and LNCaP-95 cells treated with IPI for 3 and
6 d. (C) Representative immunoblotting showing the
down-regulation of translation initiaton cofactor
eiF4B, following treatment with IPI for 6 d. Experi-
ment was repeated twice (LNCaP) and four times
(LNCaP-95). (D) Immunoblotting showing the rescue
of AR expression in LNCaP, following reduction of ER
stress using the PERK inhibitor GSK2606414 (100 nM,
24 h; 1-h pretreatment). Phosphorylation of PERK is
shown as an upward shift of the protein molecular
weight. (E) Immunoblotting showing the rescue of AR
expression in LNCaP, following reduction of ER stress us-
ing the Ca2+ chelant bapta (10, 20 μM, 12 h; 1-h pre-
treatment). Next to the immunoblotting, densitometric
analysis of p-eiF2a is shown. Values are reported as nor-
malized arbitrary units (AU). (F) Representative immu-
noblotting showing concomitant rescue of IPI-mediated
AR/AR-V7 reduction and ER stress, following incubation
with palmitate for 3 d. Palmitate (50 μM) was complexed
with BSA (molar ratio 6:1), while control cells were
treated with BSA only. (G) Schematic representation of
the involvement of ER stress in mediating IPI effects.
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increase the rate of de novo FA synthesis despite the presence of
abundant circulating FAs. This metabolic phenotype is associated
with PCa progression and androgen independence. De novo syn-
thesized FAs contribute to new membrane synthesis, are a source of
energy, promote oncogenic signaling, and contribute to drug re-
sistance (13). Thus, lipogenesis represents a PCa-specific metabolic
vulnerability that can be exploited therapeutically.
While FASN is an established therapeutic target, and FASN
inhibitors had proved promising in the preclinical setting, off-
target effects, poor solubility and pharmacokinetics, and unto-
ward effects including weight loss have prevented their clinical
development (13). Recently, newly released FASN inhibitors
such as TVB-3166 (inhibitor of the β-ketoacyl-reductase domain)
and Fasnall (a thiophenopyrimidine-based FASN inhibitor tar-
geting the nucleotide binding pockets) showed encouraging re-
sults in patient-derived non-small-cell lung cancer xenografts and
in the breast cancer murine MMTV-Neu model, respectively (22,
37). A modified, orally available version of TVB-3166, TVB-
2640, is currently in phase-I clinical trials in patients with ad-
vanced solid malignancies (NCT02223247). Combined with
paclitaxel, TVB-2640 proved beneficial in heavily pretreated
breast cancer patients (38, 39). New trials are now investigating
TVB-2640 in different stages of astrocytomas, breast, and colon
cancers (NCT03032484, NCT03179904, and NCT02980029).
However, no study has been conducted in mCRPC thus far.
We developed and characterized the selective, irreversible,
and potent FASN inhibitor IPI-9119. We show that IPI-9119
significantly reduced cell growth and induced cell cycle arrest
and apoptosis in PCa cells, while minimally affecting nontransformed
cells. As expected, FASN inhibition markedly affected lipid homeo-
stasis, including the synthesis and oxidation of FAs, as well as the
metabolism of triglycerides and phospholipids. The accumulation
of polyunsaturated FAs following IPI-9119 treatment suggests an
attempt to compensate for the reduction in newly synthesized
saturated FAs through increased uptake and utilization of exog-
enous FAs. Metabolic profiling uncovered an even broader met-
abolic rewiring, encompassing amino acid, carbohydrate, and
TCA cycle pathways. Cholesterol levels and the expression of
genes involved in steroidogenesis were increased following IPI-
9119 treatment, as previously indicated (22). This effect can be
ascribed, at least in part, to a redirection of the unused acetyl-CoA
toward cholesterol synthesis. However, increased intratumoral ste-
roidogenesis was not observed. The fate and biological implications
of enhanced cholesterol synthesis warrant further investigation.
Interestingly, while the analysis of the metabolome/lipidome is
consistent with the suppression of FASN activity, PCa cells at-
tempt to compensate for de novo FA deficiency by up-regulating
genes encoding enzymes and transcription factors involved in
lipid synthesis, as previously found (22). Therefore, transcrip-
tional changes should not be used as a readout of suppression of
FASN activity.
FASN and FA synthesis are directly and indirectly regulated by
the androgen/AR axis (19, 20). This paradigm holds true in mCRPC
with reactivated AR signaling and FASN overexpression (15, 16). In
addition, treatment with the SREBP inhibitor fatostatin and the
cholesterol synthesis inhibitor simvastatin resulted in AR-FL pro-
tein level reduction (21, 40), suggesting that modulation of lipid
metabolism may impact AR signaling.
While FASN inhibitors have shown efficacy in non-hormone-
driven tumors as well as in AR-negative PCa cells (i.e., PC3 cells)
(41), here we investigated the modulation of FA synthesis as an
indirect, alternative approach to target the AR/AR-V7 pathway
in the CRPC setting. We show that IPI-9119 results in the in-
hibition of AR-FL in both AD and AI cells harboring exclusively
AR-FL and of AR-V7 in AI models driven by the variant (i.e.,
22Rv1 and LNCaP-95). Both full-length and spliced AR protein
were diminished in AD and AI PCa cells, while AR-FL reduction
at the mRNA level was observed only in LNCaP cells. In fact, we
show that ER stress induced by IPI-9119 results in the inhibition
of protein translation and in AR/AR-V7 protein reduction. ER
stress inhibitors partially rescue AR expression, suggesting that
ER stress is involved in mediating the effect of FASN suppres-
sion on the AR pathway. The induction of ER stress had been
previously associated with the down-regulation of the AR path-







Fig. 6. IPI-9119 inhibits AR transcriptional activity and enhances Enza effi-
cacy. (A) Heat map of canonical AR target genes, following treatment with
IPI-9119 (IPI) or DMSO for 6 d. Normalized counts (n = 3) are shown. (B) Lucif-
erase activity in LNCaP cells treated with IPI for 6 d. ****P < 0.0001, one-way
ANOVA, followed by Tukey’s post hoc test. Data represent mean ± SD (n = 3). (C)
Heat map of RNA-seq data showing IPI-mediated abrogation of the AR-V7_UP
gene signature after 6 d of treatment. Normalized counts are shown (n = 3). (D)
Heat map of TaqMan Array Microfluidic Cards data showing palmitate rescue of
the AR-V7_UP gene signature. Results are expressed as fold change of DMSO
treatment. Normalized values are shown (n = 3). (E) Preranked GSEA analysis
showing IPI-mediated reversion of a gene signature associated with CRPC bone
metastases expressing high levels of AR-V7; P values are indicated. (F) Repre-
sentative immunoblotting showing the reduction of c-MYC protein expression
under treatment with IPI for 6 d. Coincubation with palmitate restored c-MYC
expression. Palmitate (50 μM) was complexed with BSA (molar ratio 6:1), while
control cells were treated with BSA only. (G) Preranked GSEA analysis showing
IPI-mediated negative modulation of MYC_TARGETs_V1 signature (Hallmarks; h.
all.v5.2s symbols.gmt); FDR values are indicated. (H) Cell growth after 6 d of Enza
and IPI cotreatment. ****P < 0.0001 IPI vs. DMSO, ##P < 0.01 Enza vs. DMSO,
$$P < 0.01 IPI+Enza vs. IPI, &&&&P < 0.01 IPI+Enza vs. Enza, two-way ANOVA
followed by Sidak’s post hoc test. n = number of independent samples.











increased degradation (29, 30). Likewise, modulation of lipid
metabolism and membrane lipid composition as well as in-
hibition of FASN activity have been all reported to trigger ER
stress (26–28, 42). In AI cells driven by AR-V7, inhibition of de
novo lipogenesis suppressed a gene signature derived from bone
metastases with high levels of AR-V7 (33), as well as previously
reported AR-V7–regulated gene signatures from in vitro models
(32, 34). In addition, combination of IPI-9119 with Enza showed
higher antitumor efficacy than monotherapy in an AR-V7–driven
22Rv1 cell line. Interestingly, IPI-9119 significantly reduced tumor
growth in preclinical CRPC models resistant to Enza/Abi without
overt side effects. Furthermore, FASN inhibition was also effec-
tive in an organoid model derived from human mCRPC. These
findings have important therapeutic implications, particularly in the
castration-resistant setting, in view of the finding that the over-
whelming majority of human CRPC metastases we examined
coexpressed FASN and AR-FL. Intriguingly, AR-V7 was pos-
itive in 39% of bone metastases, though only in a minority of
visceral sites (12%). In both, FASN was consistently coex-
pressed with AR-V7. Therefore, FASN may be targeted in the
majority of mCRPC, regardless of AR-V7 status (43). Inhibi-
tion of de novo lipogenesis could be proposed in association
with Enza and/or Abi or taxanes, to delay/overcome resistance.
Alternatively, FASN inhibition could be undertaken in tumors
that are still AR-driven once resistance has emerged. Carefully
designed clinical trials are required to establish the therapeutic
timing, combinatorial regimens, and the population suitable for
treatment with FASN inhibitors.
Finally, our data also indicate that protein expression of the
AR-dependent gene c-MYC (44) as well as the c-MYC–regulated
transcriptional signature are significantly reduced by FASN in-
activation. These data are clinically relevant because c-MYC
alterations occur in about 20% of mCRPC (45) and c-MYC
transcript levels are increased in AR-V7–high bone metastases
(33). Furthermore, overexpression of c-MYC protein was shown
to induce androgen-independent growth (46). The potential in-
volvement of c-MYC in alternative splicing and generation of
AR-V7 has also been suggested (47). Our group had previously






Fig. 7. IPI-9119 inhibits tumor growth of CRPC xenografts and human
mCRPC-derived organoids. (A) Average tumor volume of 22Rv1 xenografts
during 28-d treatment with IPI-9119 (IPI) using the ALZET s.c. pump infusion
(n = 12 vehicle, n = 11 IPI-9119). Results are expressed as n-fold the mean initial
volume (equal to 1) ± SEM. (**P = 0.0056, end of treatment, Mann–Whitney
nonparametric test). (B) Densitometric analysis of AR-FL and AR-V7 protein
expression in xenograft homogenates at the time points analyzed (**P =
0.0091, ANOVA test, followed by Tukey’s post hoc test). (C) Average tumor
volume of LNCaP-95 xenografts (n = 20 vehicle, n = 17 IPI) treated as in A.
Results are expressed as n-fold the mean initial volume (equal to 1) ± SEM
(**P = 0.0016, end of treatment, Mann–Whitney nonparametric test). (D)
Measurement of FASN activity in LNCaP-95 xenografts homogenates collected
at the end of treatment. Results are expressed as counts per minute normal-
ized to protein content ± SD (n = 20 vehicle, n = 17 IPI), ****P < 0.0001, Mann–
Whitney nonparametric test. (E) Representative image of MSK-PCa3 organoids
treated with IPI or DMSO for 25 d (Left). Statistical analysis of the organoid
sizes (Right). Diameters of organoids treated with IPI were compared with
DMSO (n = 78 DMSO-treated, n = 95 IPI-treated), ****P < 0.0001, Student




Fig. 8. FASN is coexpressed with AR-FL and AR-V7 in human mCRPCs. (A)
Status of FASN, AR-FL, and AR-V7 in metastatic sites. Data are expressed as a
percentage of either osseous or visceral metastases. (B) Representative im-
ages of FASN coexpression with AR-FL and AR-V7 (20×) in bone metastases:
Bright field (a), FASN/AR-FL staining (b), FASN/AR-V7 staining in AR-V7–
negative bone metastasis from a mCRPC Enza/Abi-naïve patient (c); bright
field (d), FASN/AR-FL staining (e), FASN/AR-V7 staining in AR-V7–positive
bone metastasis from a mCRPC Enza/Abi-naïve patient (f); bright field (g),
FASN/AR-FL staining (h), FASN/AR-V7 staining in AR-V7-positive bone me-
tastasis from a mCRPC Enza/Abi-treated patient (i). (C) Bar graph showing
the percentage of patients with FASN/AR-FL and FASN/AR-V7 coexpression
in all mCRPC patients analyzed or in the subset treated with Enza/Abi.
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pathway enrichment for FA metabolism in cell lines, murine
models, and human prostate tumors. FASN expression was also
increased in c-MYC–transformed cells, suggesting their de-
pendency on de novo lipogenesis (48). In line with this, MYC-
CaP cells were very sensitive to FASN inhibition with IPI-9119,
suggesting a mutual regulation between FASN and c-MYC.
In conclusion, FASN inhibition rewires the CRPC metabolome
and induces ER stress, resulting in the down-regulation of AR-FL/
AR-V7 and CRPC cell growth inhibition. This study sets the stage
and provides the rationale for clinical trials to test FASN inhibi-
tors in mCRPC.
Materials and Methods
Reagents. IPI-9119 (US Patent nos. 8,546,432 and 9,346,769), developed by
Infinity Pharmaceuticals, was resuspended in 100%DMSO for in vitro studies.
For in vivo studies, IPI-9119was resuspended in 20%1-methyl-2-pyrrolidinone
in 0.1 M sodium phosphate buffer, pH 8 (osmotic ALZET pump). All of the
reagents used in the paper are described in SI Appendix.
Cell Culture. Cells were cultured in standard conditions. Details are provided in
SI Appendix. All cells were authenticated using short tandem repeat pro-
filing performed by ATCC. A Mycoplasma test was performed bimonthly,
using the colorimetric MycoAlert mycoplasma detection kit (Lonza). All cells
used were tested negative.
Organoid Culture. MSK-PCa3 organoids, kindly provided by Yu Chen, Me-
morial Sloan-Kettering Cancer Center, New York, were dissociated to single
cells with trypsin for 15 min at 37 °C; 2 × 103 cells per well were mixed with
40 μL of growth factor reduced matrigel, seeded in a 24-well plate, and
cultured in human organoid culture medium (36), in the presence of
either FASN inhibitor or DMSO. Culture medium was refreshed every 3 d
for 25 d. Organoids were imaged with a Zeiss Axio microscope, and their
diameter was manually measured. Organoid samples were deidentified
before use.
Cell Growth and Clonogenic Assays. Measurement of cell growth and clono-
genic assays were performed as previously described (49), with some modi-
fications. Detailed information is provided in SI Appendix.
Cell Cycle and Apoptosis Studies. Cell cycle and apoptosis analyses were
performed as previously described (49, 50). Detailed information is provided
in SI Appendix.
Immunoblotting. Immunoblotting was performed using standard procedures.
Detailed information is provided in SI Appendix.
Analysis of Protein Synthesis (SUnSET Assay). SUnSET assay was performed
to analyze protein synthesis, as per the manufacturer’s recommendations.
Cells were treated with IPI-9119 for 3 and 6 d and then incubated with
puromycin (1 μg/mL) for 30 min, before harvesting. Cells were washed with
ice-cold PBS and lysed using 1% Nonidet P-40 buffer. An equal quantity of
protein lysates was separated on SDS/PAGE and probed with antipuromycin
antibody (kerafast).
Biochemical Assays and Oil Red O Staining. FASN activity, de novo lipogenesis,
FAO analysis, and Oil Red O staining were performed as previously de-
scribed (48–51), with some modifications. Detailed information is provided
in SI Appendix.
RNA Extraction and Real-Time qPCR. RNA extraction and real-time qPCR were per-
formedusing standardprocedures. Detailed information is provided in SI Appendix.
FASN and AR-FL/AR-V7 Genetic Manipulation. Infections were performed as
previously described (52) in biological triplicates. Details and construct in-
formation are provided in SI Appendix.
Luciferase Assay. Luciferase assay was performed using the Dual Luciferase
Assay Kit as described by the manufacturer. Detailed information is provided
in SI Appendix.
RNA Sequencing. Library preparation, sequencing, and data analysis were
performed at the Center for Cancer Computational Biology. Detailed In-
formation is provided in SI Appendix.
Metabolic Profiling. Metabolic profiling was performed by the company
Metabolon Inc., using their liquid chromatography tandem MS platforms.
Information regarding sample preparation, quality assurance, quality control,
metabolite identification/quantification, and data preprocessing is detailed
in SI Appendix.
Lipidomics. Lipids were extracted, dried under nitrogen steam, and store at
−80 °C until further analysis. Lipidomic profiling was performed by the Mass
Spectrometry, Metabolomics, and Proteomics core at Beth Israel Deaconess
Medical Center using their high-resolution hybrid QExactive Plus Orbitrap
mass spectrometer (Thermo Fisher Scientific), as described in ref. 53. Details
are provided in SI Appendix.
Animal Studies. Animal studies were performed according to ARRIVE
guidelines and approved by the Dana-Farber Cancer Institute Institutional
Care and Use Committee in accordance with the Guide for the Care and Use
of Laboratory Animals (54). Details are provided in SI Appendix.
Human Studies and Image Analysis. The human mCRPC specimens were
obtained as part of the University of Washington (UW) Medical Center
Prostate Cancer Donor Program, which was approved by the UW Institutional
Review Board. Human studies were conducted according to Declaration of
Helsinki principles. A written informed consent was received from partici-
pants before inclusion in the study. Description of the human samples and
details on immunofluorescence staining, antibody dilution, and image
analysis are provided in SI Appendix.
Statistical Analyses. A detailed description of all of the statistical analyses is
provided in SI Appendix. Differences were considered significant with P <
0.05 and, if multiple comparisons were done, FDR < 0.05. For GSEA and
MSEA, an FDR threshold of 0.15 was used.
Data and Materials Availability. RNA-seq data have been deposited in Gene
Expression Omnibus (GEO) under accession no. GSE114016 (55). Raw and
normalized metabolomics and lipidomics data are provided in Dataset S1
B and E–I.
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